Role of lapatinib alone or in combination in the treatment of HER2-positive breast cancer.

ABSTRACT:

Purpose

This review aims to present the preclinical and clinical data regarding efficacy and safety of lapatinib alone and in combination with other agents in the treatment of human epidermal growth factor receptor-2 (HER2)-overexpressing breast cancer.

Background

HER2-positive (HER2+) breast cancer remains a treatment challenge. It is more aggressive than other breast cancers and it is associated with a poor outcome. Targeted therapy for HER2+ breast cancer has significantly changed the clinical course of the disease. Despite advances in therapy, there remains an unmet need in the treatment of HER2+ breast cancer. Lapatinib is a novel, orally bioavailable epidermal growth factor receptor/HER2+ targeted agent. Many trials have investigated the efficacy and safety of lapatini

SUBMITTER: Hurvitz SA 

PROVIDER: S-EPMC3846547 | biostudies-literature | 2012 Apr

REPOSITORIES: biostudies-literature